SOHO State of the Art Updates and Next Questions: Measurable Residual Disease in Acute Lymphoblastic Leukemia - Optimization and Innovation in 2022 and Beyond

Stock, 2019, A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403, Blood, 133, 1548, 10.1182/blood-2018-10-881961 O'Dwyer, 2017, Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in older adults: Current treatment and novel therapies, Best Pract Res Clin Haematol, 30, 184, 10.1016/j.beha.2017.08.001 Gokbuget, 2012, Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation, Blood, 120, 2032, 10.1182/blood-2011-12-399287 Kantarjian, 2017, Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia, N Engl J Med, 376, 836, 10.1056/NEJMoa1609783 Shah, 2021, KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase II results of the single-arm, open-label, multicentre ZUMA-3 study, The Lancet, 398, 491, 10.1016/S0140-6736(21)01222-8 Short, 2021, Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms, Leukemia, 35, 3044, 10.1038/s41375-021-01277-3 Bartram, 2020, Monitoring MRD in ALL: Methodologies, technical aspects and optimal time points for measurement, Semin Hematol, 57, 142, 10.1053/j.seminhematol.2020.06.003 Wood, 2018, Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL, Blood, 22, 1350, 10.1182/blood-2017-09-806521 Kruse, 2020, Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia, Int J Mol Sci, 21, 1054, 10.3390/ijms21031054 Brown, 2021, Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology, J Natl Compr Canc Netw, 19, 1079, 10.6004/jnccn.2021.0042 Hoelzer, 2016, Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 27, v69, 10.1093/annonc/mdw025 Short, 2019, Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts, Am J Hematol, 94, 257, 10.1002/ajh.25338 Bruggemann, 2012, Has MRD monitoring superseded other prognostic factors in adult ALL?, Blood, 120, 4470, 10.1182/blood-2012-06-379040 Bradstock, 1981, Immunological monitoring of residual disease in treated thymic acute lymphoblastic leukaemia, Leuk Res, 5, 301, 10.1016/0145-2126(81)90002-3 van Dongen, 2015, Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies, Blood, 125, 3996, 10.1182/blood-2015-03-580027 Pongers-Willemse, 1998, Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes, Leukemia, 12, 2006, 10.1038/sj.leu.2401246 Berry, 2017, Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis, JAMA Oncol, 3, 10.1001/jamaoncol.2017.0580 Ching, 2020, Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma, BMC Cancer, 20, 612, 10.1186/s12885-020-07077-9 Short, 2020, Ultrasensitive Next-Generation Sequencing-Based Measurable Residual Disease Assessment in Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia after Frontline Therapy: Correlation with Flow Cytometry and Impact on Clinical Outcomes, Blood, 136, 26, 10.1182/blood-2020-141971 Short, 2022, High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse, Blood Adv, 6, 4006, 10.1182/bloodadvances.2022007378 Bader, 2019, More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling, Blood Adv, 12, 3393, 10.1182/bloodadvances.2019000449 Sekiya, 2017, Clinical utility of next-generation sequencing-based minimal residual disease in paediatric B-cell acute lymphoblastic leukaemia, Br J Haematol, 176, 248, 10.1111/bjh.14420 Raff, 2007, Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials, Blood, 109, 910, 10.1182/blood-2006-07-037093 Pemmaraju, 2017, Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission, Am J Hematol, 92, 279, 10.1002/ajh.24629 Logan, 2014, Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival, Biol Blood Marrow Transplant, 20, 1307, 10.1016/j.bbmt.2014.04.018 Muffly, 2021, Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia, Blood Adv, 5, 3147, 10.1182/bloodadvances.2021004234 van der Velden, 2002, Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL, Leukemia, 16, 1432, 10.1038/sj.leu.2402636 Muffly, 2020, How I Approach the Patient Who Has MRD or Relapse After Transplant, Clin Lymphoma Myeloma and Leukemia, 20, S32, 10.1016/S2152-2650(20)30453-5 Rives, 2021, CAR T cells in CNS-relapsed leukaemia: one step forward, The Lancet Haematology, 8, e675, 10.1016/S2352-3026(21)00281-7 Thastrup, 2020, Flow cytometric detection of leukemic blasts in cerebrospinal fluid predicts risk of relapse in childhood acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology study, Leukemia, 34, 336, 10.1038/s41375-019-0570-1 Garcia, 2020, Blood, 136, 28, 10.1182/blood-2020-137780 Garcia, 2022, Cerebrospinal fluid flow cytometry and risk of central nervous system relapse after hyperCVAD in adults with acute lymphoblastic leukemia, Cancer, 128, 1411, 10.1002/cncr.34073 Saygin, 2022, Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients, Haematologica, 10.3324/haematol.2022.280638